

Supplementary Table 2. Clinical outcomes at 6 months

Outcomes	Checklist group (n = 537)	Non-checklist group (n = 187)	p value
Primary outcome ^{a)}	148 (27.6)	68 (36.4)	0.026
Secondary outcomes			
All cause of death	44 (8.2)	22 (11.8)	0.143
Rehospitalization	115 (21.4)	49 (26.2)	0.188
Heart failure medications			
RAAS inhibitors	316 (58.8)	83 (44.4)	0.001
ACEi/ARBs	214 (39.9)	64 (34.2)	0.191
ARNI	103 (19.2)	19 (10.2)	0.004
SGLT2 inhibitors	137 (25.7)	29 (15.6)	0.005
Beta blockers	365 (68.0)	103 (55.1)	0.002
MRA	229 (42.6)	66 (35.3)	0.084
Diuretics	341 (66.9)	122 (65.2)	0.718
ICD or CRT	53 (10.1)	15 (8.7)	0.660
Heart rate score			0.007
0	175 (32.6)	85 (45.5)	
1	68 (12.7)	24 (12.8)	
2	188 (35.1)	56 (29.9)	
3	105 (19.6)	22 (11.8)	
No. of GDMT			< 0.001
0	51 (9.5)	39 (20.9)	
1	123 (22.9)	58 (31.0)	
≥ 2	363 (67.6)	90 (48.1)	
GDMT adequacy score 1			< 0.001
0	58 (10.8)	42 (22.5)	
1	33 (6.1)	9 (4.8)	
2	98 (18.2)	48 (25.7)	
≥ 3	348 (64.8)	78 (41.7)	
GDMT adequacy score 2			< 0.001
0	57 (10.6)	42 (22.5)	
1	78 (14.5)	34 (18.2)	
2	106 (19.7)	41 (21.9)	
≥ 3	296 (55.1)	70 (37.4)	
Vital signs at discharge			
SBP (mmHg)	117.4 ± 17.9	121.2 ± 21.5	0.002
DBP (mmHg)	69.9 ± 10.2	72.0 ± 11.3	0.019

Values are presented as number (%) or mean ± standard deviation.

RAAS, renin-angiotensin aldosterone system; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; SGLT2i, sodium-glucose cotransporter-2 inhibitors; MRA, mineralocorticoid receptor antagonist; ICD, implantable cardioverter defibrillator; CRT, cardiac resynchronization therapy; GDMT, guideline-directed medical therapy; SBP, systolic blood pressure; DBP, diastolic blood pressure.

^{a)}Primary outcome is defined as a composite of all-causes of death or rehospitalization for heart failure

^{b)}Heart rate score was assessed using the same criteria as the evaluation of GDMT adequacy score in Supplementary Table 1.